Key result
High-dose corticosteroids remain first-line for ICI-associated myocarditis but resistance often requires escalated immunosuppression.
Why the study?
Immune checkpoint inhibitor-associated myocarditis poses significant challenges for therapeutic decision-making, where evidence for rescue therapies is largely limited to case reports and small series.
Design
Review
Authors
Loading...
Early corticosteroids may improve ICI-myocarditis outcomes; leaves open optimal rescue strategies pending prospective trials.
This review highlights the critical role of early high-dose corticosteroids in ICI-associated myocarditis and outlines emerging rescue therapies and rechallenge considerations amidst a lack of robust prospective evidence.
Mincu et al. (2026) conducted a review in Immune checkpoint inhibitor-associated myocarditis. Immunosuppressive therapies was evaluated. High-dose corticosteroids remain first-line therapy for ICI-associated myocarditis, but steroid resistance often requires escalation to second- and third-line immunosuppression or rescue therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: